Document is current
Any future updates will be listed below
-
Authors
Haba, Tomoyuki
Yamakawa, Kengo https://orcid.org/0009-0002-0352-1613
Ozeki, Sayako
Sumida, Akira
Kato, Takehiro
Kuroda, Eiji
Maruyama, Takako
Murakami, Takaaki
Yabe, Daisuke
- License Information
-
More Information
Article History
Received: 13 November 2023
Accepted: 2 April 2024
First Online: 21 April 2024
Declarations
:
: DY has received consulting/lecture fees from Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Sanofi K.K., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., research funding from TERUMO CORPORATION, Nippon Boehringer Ingelheim Co., Ltd. and endowed departments by commercial entities from Novo Nordisk Pharma Ltd., Taisho Pharmaceutical Co. Ltd., Arkray Inc.. TH, KY, SO, AS, TK, EK, TM and TM declare that they have no conflict of interest. All authors declare that they have no competing interests relevant to this study.
: Formal ethics approval was waived for this paper by the ethics committee of Gifu University Graduate School of Medicine due to its being a case report. All procedures performed in studies involving human participants followed the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from the patient.
